Type 2 Diabetes

Canagliflozin may reduce albuminuria and patient-specific eGFR decline in patients with type 2 diabetes and microalbuminuria, researchers found in a parallel, open-labeled trial.

A novel once-weekly basal insulin conferred noninferior HbA1c reductions compared with daily insulins for insulin-naive adults with type 2 diabetes and those who switched from daily injections, according to topline results from two trials.

Adults with prediabetes and overweight or obesity who take the GIP/GLP-1 dual agonist tirzepatide once weekly may be 94% less likely to develop type 2 diabetes, according to results from the SURMOUNT-1 study.

The FDA has cleared an automated insulin delivery system for adults aged 18 years and older with type 2 diabetes, Insulet Corp. announced.

SGLT2 inhibitors and dulaglutide confer a similar risk for dementia among adults aged 60 years and older with type 2 diabetes, according to findings published in Annals of Internal Medicine.

Preexisting diabetes was associated with a more than tripled odds of experiencing stillbirth or perinatal mortality, with higher risks for mothers with type 2 vs. type 1 diabetes, researchers reported in Obstetrics & Gynecology.

Beginning in 2026, prices for 10 drugs will be reduced for Medicare Part D recipients, according to a CMS press release.

Adults with prediabetes and overweight or obesity have a 94% lower risk for developing type 2 diabetes with the once-weekly GIP/GLP-1 dual agonist tirzepatide vs. placebo, according to top-line results from the SURMOUNT-1 3-year study.

A higher intake of heme iron may be linked to an increased risk for developing type 2 diabetes, study results published in Nature Metabolism showed.